Posts tagged coriolus versicolor psk

Coriolus Versicolor PSK – How it Works (Mechanisms Of Action) – MD Anderson

The Prevention and cancer control properties of Coriolus Versicolor PSK have been associated with its antioxidant and free radical scavenging properties in vitro and in vivo. PSK has demonstrated prevention of chemically induced DNA damage (sister chromatid exchanges) and subsequent tumors due to chemicals, radiation or other causes.

Coriolus PSK also seems to work in multiple steps of the malignant process by inhibiting adhesion, invasion, motility, and metastatic growth of tumor cells in animal models of cancer. Adhesion and invasion are inhibited by suppression of cell matrix-degrading enzyme production by malignant cells. Motility of malignant cells and subsequent attachment to blood vessels are inhibited by suppression of tumor-cell induced platelet aggregation and anti-angiogenic factors.

PSK has also induced apoptosis (programmed cell death) in lymphoma, leukemia and pancreatic cells.
Immune responsiveness of the host does not appear to be affected by PSK under normal conditions, but immune systems depressed by tumor-burden or chemotherapy, have reportedly been restored to normal levels by PSK in animal studies.
A variety of other mechanisms have been observed in laboratory studies of PSK. It was found to alter the expression of the p53 gene21, inhibit Epstein-Barr virus induced B-cell proliferation22 and suppress heat shock proteins that are thought to be involved in the progression of fibrosis. PSK has also been observed to stimulate differentiation (orderliness) of human myeloblastic leukemic cells.

When injected directly into a tumor, PSK produces local inflammatory responses that result in the non-specific killing of tumor cells. One study on vaccine therapy against cancer found that PSK promotes the maturation of dendritic cells to produce IL-12 and Th1 type cytokines.

Source: ( www.mdanderson.org)

See Also:

PSK PSP – Different Extractions of Coriolus Versicolor

Best Places to Buy Coriolus PSK

New Coriolus Immune System Builder, InForce Is Ready To Ship

The new Coriolus Vericolor product supplied by inLife LLC called inForce is now ready for shipping from its wharehouse in California. The forst of two products, the inForce immune system builder is a proprietary extract of Coriolus PSK and PSP and can be used as a daily dietary supplement.

Coriolus versicolor Immune System Builder uses mycelium extraction.

Coriolus versicolor Immune System Builder uses mycelium extraction.

Following shortly thereafter, inLife will be launching its Platinum Builder which is a PSP extract dietary supplement under exclusive licence with Dr Yang, the Chinese scientist who discovered, developed and patented the extraction process for Coriolus PSP.

See – Best Places To buy Coriolus for Link To Purchase

Visit: More Information on Inlife Coriolus Products

Trametes Versicolor PSK & Gastric Cancer

Numerous clinical trials have been carried out over the years with PSK derived from Trametes versicolor (Coriolus versicolor, Poyporous Versicolor, Turkey tail, Yun Zhi) and are briefly summarised below:

PSK:

There have been several decades of successful clinical trials using PSK to treat head and neck, upper GI, colo-rectal and lung cancers with some reported success in treating breast cancer as well.  Clinical trials with PSK have recently been extensively reviewed by Kidd (2000) and will be briefly summarised here.  Almost exclusively, clinical trials have been carried out in Japan.

PSK and gastric cancer:

PSK has been used as a form of immunotherapy for more gastric cancer patients than any other cancer type.  In early 1970s Kaibara’s group began trialing PSK with their existing chemotherapy regimens for stage IV disease (Kaibara et al., 1976).  After surgical resection (partial or full gastrectomies), PSK at 3g per day was added to a chemotherapy regimen of Mitomycin C and 5-fluorouracil (5-FU) (n=66). When compared with a historical control group, the 2 year survival rate was more than double, a finding that was later confirmed by Fujimoto et al. (1979) in a larger prospective study (n= 230).  Further studies by Hattori et al. (1979) (n=110) and Kodama et al. (1982) (n =450) suggested that PSK gave some protection against the immunosuppression that normally is associated with surgery and long-term chemotherapy.

One of the few double-blind randomised controlled trials (n=144) examining the role of single agent PSK found a significant increase in disease-free and overall survival.  PSK had significant effects on these patients immune systems as measured by increased delayed-type hypersensitivity on skin tests and enhanced chemotactic migration of neutrophils (Kondo and Torisu, 1985). All these studies suggest that individuals with very low immunity are less likely to benefit from PSK therapy than individuals with a reasonably competent immune system.  Other non- randomised trials in Japan have supported these findings (Mitomi and Ogoshi, 1986; Niimoto et al., 1988; Maehara et al., 1990; Nakazato et al., 1994).  Tsujitani et al. (1992) had previously observed that dendritic cells could infiltrate gastric cancers in some patients and biopsy examination correlated this dendritic infiltration of their tumours with an increase in disease-free and overall survival post-surgery.  It was concluded that patients with gastric cancer with limited dendritic cell infiltration prior to surgery when given PSK immunotherapy were more likely to have significant response.  The most recent phase III 2 arm trial of PSK in the treatment of gastric cancer carried out by the “Study Group of Immunochemotherapy with PSK for Gastric Cancer of Japan” showed that combining PSK with conventional chemotherapy significantly improved disease-free and overall survival (Nakazato et al., 1994).

PSK and other cancers

In a non-controlled, retrospective analysis of combined radiation, chemotherapy and immunotherapy (using PSK or OK-32, another immuno- potentiator) with 133 patients with oesophageal cancer, there were improvements in one-year and two-year survival (Okudaira et al., 1982).  In another more recent study PSK improved overall survival in oesophageal cancer in patients with levels of pre-operative high α1-anti-chymotrypsin or sialic acid (Ogoshi et al., 1995).  In a small scale trial in Taiwan for nasopharngeal carcinoma PSK adjunct therapy had a small but significant impact on five-year survival (Go and Chung, 1989).

In a study of 185 patients with epidermoid carcinoma, adenocarcinoma or large-cell carcinoma ( IIIb) given PSK as an immune system potentiator following radiotherapy, almost four times more patients who were treated with PSK had significant improvements in disease-free survival than those not given PSK (Hayakawa et al., 1993).  PSK was clinically significant with more advanced patients with Stage III disease than Stage I and II patients.  PSK had greater activity for older patients (> 70 years) and patients with small primary tumours. Early studies with breast cancer patients seemed to imply that long-term PSK immunotherapy in conjunction with chemotherapy could have beneficial results (Suginachi et al., 1984).  In a later much larger trial (914 patients) in-depth analysis implied that PSK significantly extended survival in ER-negative, Stage IIA patientswithout lymph node involvement (Toi et al., 1992).  However, in a further large trial, Morimoto et al. (1996) could find no statistical evidence of any benefit from PSK.

These contradictory studies may have been clarified by Yokoe et al. (1997) who compared HLA B40 antigen positive patients treated with PSK against B40 negatives.  It was found that B40-positive patients treated with PSK (3g/daily, two month course each year) in addition to chemotherapy had an improved 10 year overall survival rate compared to B-40 negative patients.  Thus, HLA B40 may be a predictive factor for PSK response.

The foregoing studies give strong indications of the potential benefits of incorporating PSK into some cancer treatments as an adjunct to radio- or chemotherapy.  Furthermore, PSK can improve immune status secondary to the side effects associated with traditional therapies.  As stated by Kidd (2000)  “after a quarter century of trials indicating PSK can improve cancer survival, the cumulative human findings amount to a recommendation for its inclusion in standard anticancer protocols. With its risk for adverse effects virtually nonexistent, PSK’s contribution to the benefit-risk profiles of these protocols can only be positive”.


Extracts taken from: THE ROLE OF POLYSACCHARIDES DERIVED FROM MEDICINAL MUSHROOMS IN CANCER (icnet.uk)

Coriolus Versicolor – The Miracle Mushroom

This extract taken from quantumhealing.co.za details various trials and treatments of Coriolus Versicolor.

It shrank his liver tumor by 90%––after his doctor gave up on him.

A man describes his oncologist as “the most negative man I ever met.” The doctor treated Mr. G. for liver cancer for six years, then gave him up as untreatable. “After the chemo failed, he threw up his hands, shrugged his shoulders, wished me good luck, and said there was nothing else he could do,” according to Mr. G. “And surgery couldn’t be performed either, because the consulting surgeon saw that the tumor was wrapped around my vena cava blood vessel.”

Mr G. told his oncologist, “I totally reject what you are telling me. I do not accept that nothing can be done to affect the outcome of this disease.” The doctor said, “Well, I know what I’m talking about when it comes to cancer. I’m a scientist.”

Mr G. shot back, “Yes, but you’re not God!” Four years later the patient was healthy again after using the type of therapies known as CAIM (complementary/ alternative/integrative medicine), especially including capsules containing the powdered extract of a mushroom, Coriolus versicolor. Mr G. learned about the remedy on the Internet and he can tell you all about it, having downloaded nearly 400 studies.

Amazingly, Mr. G.’s liver cancer reduced to less than ten percent of its original size. His CEA (carcinoembryonic antigen) cancer marker fell more than two-thirds from 296 to 97.9.

What is Coriolus Versicolor?

Like all mushrooms, Coriolus versicolor is a fungus, one of more than a half million varieties worldwide. Many of them have been known for thousands of years to have medicinal properties. And as you may know, gourmets the world over prize both wild and commercially grown mushrooms. Some European cookbooks even call them “flowers of the fall.” Whatever you call them, certain mushrooms are a perfect food for staying trim and healthy. They have little or no fat and some species, like Coriolusversicolor, boast valuable therapeutic and nutritional benefits. But a few fungi are poisonous and we do not recommend that nonexperts attempt to harvest their own. Coriolus versicolor goes by a number of botanical names, including Trametes versicolor and Boletus versicolor.

“Versicolor” refers to the mushroom’s various colors. In North America, the common name is “turkey tail,” while in Japan it is called by a name meaning “mushroom by the river bank” and in China its name indicates it’s a cloud fungus that grows best in the rain.

Over 400 clinical studies have shown that a purified extract derived from the mushroom Coriolus versicolor offers strong benefits for the immune system. Clinical studies indicate the extract’s ingredients are especially effective against stomach, uterine, colon and lung cancer.

Anecdotal evidence and clinical experience suggest it also works well against prostate, breast, liver and colorectal  cancer. Studies of rats and mice show that this mushroom is effective against many experimental animal cancers such as sarcoma and hepatoma.

Martha I.’s lung cancers disappear

“Of course,” says Dr. Bailey, “some cancer patients take Coriolus versicolor even while they engage in radiation treatment or chemotherapy. Or the patients don’t submit to chemotherapy or radiotherapy at all but rely, instead, exclusively on nutritional therapies with the medicinal mushroom as the main treatment ingredient.

“For example, one of my patients, Martha I., a 34-year-old woman working in the health field, consulted me with a cancer spreading at two sites in her lungs. Orthodox treatment had been tried but no longer was effective. She discontinued her smoking of two cigarette packs a day and embarked on nutritional therapies.

The nutrients included Martha’s completing six months of taking Coriolus versicolor. After this halfyear, radiological examination showed that all of her lung tumors had disappeared. Seeing her current progress, orthodox medicine probably would declare this patient to be cured.”

Blood tests show how the mushroom boosts immunity

I spoke with a doctor who measures natural killer cell (NK) counts and considers them a valuable cancer

marker. Kenneth Bock, M.D., is the medical director of two holistic medical clinics, one in Rhinebeck, New York and the other in Albany. “Because it increases natural killer (NK) cell activity, I think of using Coriolus versicolor mainly when I’m confronted with a patient suffering from cancer or a viral infection,” he says. “This mushroom is one of the main medicinal compounds I use to boost a diminished blood reading which records NK activity. The mushroom’s active biological response modifier produces a marked improvement in NK cell function and number, something I monitor by blood testing. If the blood reading is low, my patient takes greater amounts of PSK capsules. And, although it’s an expensive and sophisticated assay, I repeat my NK cell testing inside of a month or two. In a number of patients, I’ve seen some nice blood test improvement.”

Dr. Bock finds that a few patients with advanced metastatic cancer see their NK counts jump from 2 or 3 to a normal 20 to 50.

Patient’s immune system recovers

“I can illustrate what I’m saying by providing a before-and-after case history plus the literature that backs my claim,” Dr. Bock states. His patient was a white, married computer consultant named Marty E., sixty years old and suffering from high blood pressure and arteriosclerosis when he was also found to have polyps on his larynx. These were removed, with radiation therapy as a follow-up. But then Marty E. was also found to have prostate cancer.

“His blood test showed diminished natural killer cell activity at the level of 6 m/u,” Dr. Bock states. “Still, Marty wanted no conventional therapy for prostate cancer. So I started him on alternative medical therapies for prostate cancer and to improve his deficient NK cell activity. Coriolus versicolor was a definite part of his treatment regimen.

“Within two months, the patient’s NK cell activity elevated to 18 m/u. And two months after that his NK cell activity increased to a normal 31 m/u. Now the man is doing well physically, and he tells me he feels great! I would say this type of response to the  PSK therapy is usual; the patient’s quality of life does improve dramatically and he or she feels asense of well-being,” according to Dr. Bock.

A naturpathic doctor named Tori Hudson told of her clinical experience using PSK for breast cancer patients during and after chemotherapy. “My impression is that patients taking Coriolus versicolor are experiencing less side effects from chemotherapy such as diminished fatigue, less nausea (but not less hair loss), and more stable white blood cell counts. I have not measured natural killer cell counts,” she states.

Animal studies confirm what patients see for themselves

Animal studies show PSK is effective against a long list of cancers including melanoma, sarcoma, mammary cancer, colon cancer and lung cancer. Studies also show it inhibits metastasis to other sites. The studies indicate PSK enhances the immune system and battles cancer cells. It’s been shown to prolong the survival time and stimulate the production of cancer antibodies in mice with cancer.

PSK is also a potent antiviral remedy that may hold new hope for HIV-AIDS. It even lowers cholesterol in animals and speeds up recovery from burns in rabbits when used in combination with the herb Astragalus membranaceus.

Can be used in combination with conventional treatments

Human patients who have decided to stick with conventional chemotherapy and radiation therapy need to know that PSK renders these toxic treatments much more effective, as shown by a number of clinical studies.

A Japanese study looked at the effectiveness of 200 phytochemicals (plant substances) when used in combination with chemotherapy and radiation. Coriolus versicolor was found to be the best of the bunch. The researchers suggest that this medicinal mushroom seems to protect the immune system from being suppressed by prolonged use of chemotherapy drugsand by the cancer itself.

Further investigations indicate a marked improvement in the survival rates of chemo and radiationpatients taking the mushroom therapy when compared with those who did not. For patients with Stage I lung cancer observed over ten years, the tumor shrinkage and survival rate was 39 percent for those taking PSK compared to only 16 percent for patients receiving the toxic therapies without the mushroom extract. That’s a huge difference––more than twice as many survived and/or improved with the help of PSK.

Those lung cancer patients with more serious Stage II cancer experienced a 22 percent tumor shrinkage and survival rate over ten years when they took Coriolus versicolor orally while being treated with chemo or radiation. Among the people who didn’t take the herbal remedy the figure was a mere five percent.

From this study of 185 lung cancer patients it appears the mushroom extract can make the toxic therapies anywhere from two to four times more effective.

A Japanese study of 262 gastric cancer patients tested the mushroom’s efficacy following surgery. During a follow-up period ranging from five to seven years, the half who received the mushroom extract survived at substantially higher rates. The researchers concluded that PSK was a useful adjunctive therapy to surgery and chemo.

A Japanese study of breast cancer patients found similar results: Those who received PSK along with chemotherapy had better outcomes than those who did not. And a study of 28 patients suffering from acute leukemia––all on chemotherapy––showed an average survival time of 21 months for those who took the mushroom extract and 12 months for those who did not.

Rss Feed Tweeter button Facebook button Technorati button Linkedin button Webonews button Delicious button Digg button